Compare Gigacloud Technology Inc (GCT) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gigacloud Technology Inc vs Sanofi SA — how do they compare? Gigacloud Technology Inc trades at $56.94 (market cap $2.02B), while Sanofi SA trades at $40.15 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 47.1× Gigacloud Technology Inc's market cap, and Sanofi SA pays a 6.01% dividend while Gigacloud Technology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gigacloud Technology Inc for 21 Days and Sanofi SA for 94 Days on average.
| GCT | SNY | |
|---|---|---|
Market Cap | $2.02B | $95.18B |
Volume | 1,020,985 | 2,995,646 |
Sector | Technology | Health |
52-Week High | $56.42 | $52.34 |
52-Week Low | $25.46 | $39.51 |
Typical Hold Time | 21 Days | 94 Days |
Enterprise Value | $2.14B | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GigaCloud Technology (GCT) trades at $55.65, down 0.55% on the day, with a bullish technical outlook from moving averages and a consensus analyst rating of Buy. The stock shows strong fundamentals with a P/E of 13.44, net income margin of 10.65%, and consistent earnings beats in recent quarters. Revenue is projected to grow from $1.29B in 2025 to $1.5B in 2026, while operating cash flow remains robust at $190.66M.
The investment outlook is positive given valuation attractiveness and earnings momentum, but risks include insider selling and reliance on international expansion. Analyst price targets suggest potential upside to $32.50 consensus, though the current price exceeds this, indicating mixed signals. Key catalysts are EU market growth and continued execution against guidance.
SNY trades at $40.17, down slightly by 0.07%. The technical outlook is bearish, with price near key support at $40. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21, and revenue for 2025 reached $46.72B. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling growth potential beyond its blockbuster drug Dupixent.
The stock presents a mixed outlook. Positive factors include consistent earnings beats, a high gross margin of 72.77%, and strategic partnerships. However, a bearish technical signal, a projected net income decline to $4.0B in 2026, and a high proportion of analyst hold ratings (51.86%) suggest caution. Key risks involve execution of new drug pipelines and future patent expirations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gigacloud Technology Inc
Gigacloud Technology operates a global B2B e-commerce marketplace for large-parcel goods. It provides a comprehensive solution for furniture manufacturers and retailers with integrated logistics and fulfillment.
Read more on GCT →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
